Uptake of rosuvastatin by isolated rat hepatocytes: Comparison with pravastatin

Xenobiotica

Volumn 33, Issue 4, 2003, Pages 379-388

  Nezasa, K ^a   Higaki, K ^b   Takeuchi, M ^a   Nakano, M ^a   Koike, M ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; ROSUVASTATIN;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION TRANSPORT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG ISOLATION; DRUG TOLERABILITY; DRUG UPTAKE; DYSLIPIDEMIA; ENZYME INHIBITION; MALE; MEDIATOR RELEASE; MICHAELIS CONSTANT; NONHUMAN; RAT; TARGET CELL;

ANIMALIA;

EID: 0038171260     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825031000066259     Document Type: Article

References (20)

1. ABE, T., KAKYO, M., TOKUI, T., NAKAGAMI, R., NISHIO, T., NAKAI, D., NOMURA, H., UNNO, M., SUZUKI, M., NAITOH, T., MATSUNO, S. and YAWO, H., 1999, Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. Journal of Biological Chemistry, 274, 17159-17163.
2. BRADFORD, M. M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
3. BROWN, C. D. A., WINDASS, A., BLEASBY, K. and LAUFFART, B., 2001, Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atherosclerosis Supplements, 2, 90 (abst P174).
4. DEDRICK, R. J., ZAHARKO, D. S. and LUTZ, R., 1973, Transport and binding of methotrexate in vivo. Journal of Pharmaceutical Sciences, 62, 882-890.
5. KAKYO, M., SAKAGAMI, H., NISHIO, T., NAKAI, D., NAKAGOMI, R., TOKUI, T., NAITOH, T., MATSUNO, S., ABE, T. and YAWO, H., 1999, Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2). FEBS Letters, 445, 343-346.
6. KOMAI, T., SHIGEHARA, E., TOKUI, T., KOGA, T., ISHIGAMI, M., KUROIWA, C. and HORIUCHI, S., 1992, Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochemical Pharmacology, 43, 667-670.
7. MCTAGGART, F., BUCKETT, L., DAVIDSON, R., HOLDGATE, G., MCCORMICK, A., SCHNECK, D., SMITH, G. and WARWICK, M., 2001, Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. American Journal of Cardiology, 87(Suppl.), 28B-32B.
8. MOLDEUS, P., HOGBERG, J. and ORRENIUS, S., 1978, Isolation and use of liver cells. Methods in Enzymology, 52, 60-71.
9. NEZASA, K., TAKAO, A., KIMURA, K., TAKAICHI, M. and KOIKE, M., 2002a, Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica, 32, 715-727.
10. NEZASA, K., HIGAKI, K., MATSUMURA, T., INAZAWA, K., HASEGAWA, H., NAKANO, M. and KOIKE, M., 2002b, Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metabolism and Disposition, 30, 1158-1163.
11. OLSSON, A. G., PEARS, J., MCKELLAR, J., MIZAN, J. and RAZA, A., 2001, Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. American Journal of Cardiology, 88, 504-8.
12. PAOLETTI, R., FAHMY, M., MAHLA, G., MIZAN, J. and SOUTHWORTH, H., 2001, ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines. Journal of American College of Cardiology, 37(Suppl. A), abst 1261-174.
13. SEGLEN, P. O., 1973, Preparation of rat liver cells. Experimental Cell Research, 82, 391-398.
14. SEGLEN, P. O., 1976, Preparation of isolated rat liver cells. Methods in Cell Biology, 13, 2-83.
15. SUGIYAMA, Y. and ITO, K., 1998, Future prospects for toxicokinetics: prediction of drug disposition and adverse effects in humans from in vitro measurements of drug metabolism, transport and binding. Journal of Toxicological Sciences, 23, 647-652.
16. TOKUI, T., NAKAI, D., NAKAGOMI, R., YAWO, H., ABE, T. and SUGIYAMA, Y., 1999, Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharmaceutical Research, 16, 904-908.
17. WATANABE, M., KOIKE, H., ISHIDA, T., OKADA, T., SEO, S. and HIRAI, K., 1997, Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorganic and Medical Chemistry, 5, 437-444.
18. YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, Y. and UNO, T., 1981, A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics, 4, 879-855.
19. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. American Journal of Physiology, 264, G36-G44.
20. YAMAZAKI, M., SUZUKI, H., SUGIYAMA, Y., IGA, T. and HANANO, M., 1992, Uptake of organic anions by isolated rat hepatocytes. A classification in terms of ATP-dependency. Journal of Hepatology, 14, 41-47.